WARSAW, March 12, 2021 - Greenberg Traurig advised mBank S.A. acting as the Manager of the Offering in the offering, through an accelerated bookbuilding process, of newly issued Mabion S.A. shares. The Investors have declared their subscription for all offered 2.43 million shares and the issue price has been set nearly 2.5 times higher than the minimum price calculated in accordance with the authorization expressed in the resolution of the Extraordinary General Meeting of the Company.
The value of the Transaction amounted to over PLN 130 million.
The Greenberg Traurig Warsaw team consisted of Partner Paweł Piotrowski and Associate Jakub Tarłowski.
Mabion is the first Polish biotechnology company active in the development and implementation of the latest generation of biotech drugs based on monoclonal antibody technology. In March 2021 Mabion entered into a framework agreement with Novavax regarding the production of technical batches of antigen for Novavax’ COVID-19 vaccine candidate.